Dublin, Feb. 26, 2026 (GLOBE NEWSWIRE) -- The "PD-L1 Biomarker Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031" has been added to ResearchAndMarkets.com's ...
Guideline updates discussed Thursday at the 2019 National Comprehensive Cancer Network Annual Conference reflect recent practice-changing clinical trials involving pembrolizumab and chemotherapy. The ...
The pros and cons of conducting PD-L1 testing in patients with non-small cell lung cancer. Hossein Borghaei, DO, MS: As far as PD-L1 testing, I’m pretty sure I know how it is at your center because we ...
The Dako PD-L1 IHC 22C3 PharmDx Assay has been approved as a companion diagnostic to identify patients with with locally advanced or metastatic urothelial carcinoma who are cisplatin-ineligible for ...
TUCSON, Ariz., Sept. 28, 2017 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX:RHHBY) today announced the expanded use of the VENTANA PD-L1 (SP142) Assay in non-small cell lung cancer (NSCLC) and metastatic ...
In 2017, Sanofi Genzyme launched a phase 2 clinical trial of a drug designed to target a specific genetic mutation in some patients with Parkinson's disease (PD). Researchers hoped the drug would slow ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results